Trial Profile
A Phase 1b, Open-label, Dose-finding Study of AMG 706 in Combination With Gemcitabine and Erlotinib to Treat Subjects With Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Motesanib (Primary) ; Erlotinib; Gemcitabine
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Amgen
- 16 Nov 2010 New trial record